{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T06:26:54Z","timestamp":1786688814927,"version":"build-2736575974"},"reference-count":83,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The pathological interplay between \u03b1-synuclein aggregation and iron dysregulation is central to the neurodegenerative process in Parkinson\u2019s disease (PD). Quantitative susceptibility mapping (QSM) allows\n                      <jats:italic>in vivo<\/jats:italic>\n                      assessment of regional brain iron burden, and blood assays enable measurement of plasma \u03b1-synuclein; however, their clinical relevance and mutual relationship remain insufficiently defined.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate plasma \u03b1-synuclein as a diagnostic biomarker (against controls) and to explore whether regional brain iron deposition, measured by QSM, correlates with clinical features and plasma \u03b1-synuclein within the PD group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Fifty-two PD patients and sixty-two age- and sex-matched healthy controls were enrolled. Plasma \u03b1-synuclein concentrations were quantified by ELISA. Magnetic susceptibility values of seven deep gray-matter nuclei were obtained using QSM reconstructed from a multi-echo gradient-echo sequence on a 3.0 T MRI scanner. Motor and non-motor symptoms were assessed using MDS-UPDRS-III, H-Y staging, MoCA, MMSE, HAMD, and HAMA scales.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Plasma \u03b1-synuclein levels were significantly higher in PD than controls [median 54.9 (46.9\u201360.6) vs. 28.7 (24.4\u201333.7) pg\/\u03bcL,\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.001]. ROC analysis showed strong diagnostic accuracy (AUC = 0.976, sensitivity = 100%, specificity = 88.7%). Within PD, plasma \u03b1-synuclein correlated inversely with Age (\n                      <jats:italic>r<\/jats:italic>\n                      = \u22120.371,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.007) but not with other clinical parameters. In unadjusted analyses, regional QSM values showed nominal associations with motor severity and cognitive performance; however, these associations did not remain significant after adjustment for age and multiple comparisons.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Elevated plasma \u03b1-synuclein provides a highly discriminative diagnostic biomarker for PD, while regional iron accumulation measured by QSM-derived magnetic susceptibility exhibited nominal associations with clinical and cognitive measures, although these relationships did not remain significant after age adjustment and correction for multiple comparisons. The absence of a direct association between peripheral \u03b1-synuclein levels and regional brain iron burden suggests that these biomarkers may reflect partially independent pathological processes in Parkinson\u2019s disease. Future longitudinal studies are warranted to clarify the temporal dynamics and potential complementary roles of these biomarkers in disease characterization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnagi.2026.1740309","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T05:31:44Z","timestamp":1786685504000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Plasma \u03b1-synuclein and QSM-derived susceptibility in Parkinson\u2019s disease: associations with clinical features"],"prefix":"10.3389","volume":"18","author":[{"given":"Xingjun","family":"Li","sequence":"first","affiliation":[{"name":"Neuroscience Center, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianfei","family":"Luo","sequence":"additional","affiliation":[{"name":"Neuroscience Center, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Bai","sequence":"additional","affiliation":[{"name":"Neuroscience Center, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/1531-8257(200009)15:5<977::aid-mds1032>3.0.co;2-q","article-title":"Isolation and 13C-NMR characterization of an insoluble proteinaceous fraction from substantia nigra of patients with Parkinson\u2019s disease.","volume":"15","author":"Aime","year":"2000","journal-title":"Mov. Disord."},{"key":"B2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jns.2018.01.019","article-title":"Quantifying iron deposition within the substantia nigra of Parkinson\u2019s disease by quantitative susceptibility mapping.","volume":"386","author":"An","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/mds.22872","article-title":"Hippocampal, caudate, and ventricular changes in Parkinson\u2019s disease with and without dementia.","volume":"25","author":"Apostolova","year":"2010","journal-title":"Mov. Disord."},{"key":"B4","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1091\/mbc.e03-02-0078","article-title":"Inhibition of proteasomal activity causes inclusion formation in neuronal and non-neuronal cells overexpressing Parkin.","volume":"14","author":"Ardley","year":"2003","journal-title":"Mol. Biol. Cell"},{"key":"B5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/2045-8118-11-17","article-title":"Brain disposition of \u03b1-synuclein: roles of brain barrier systems and implications for Parkinson\u2019s disease.","volume":"11","author":"Bates","year":"2014","journal-title":"Fluids Barriers CNS"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s13311-018-0656-x","article-title":"Marked age-related changes in brain iron homeostasis in amyloid protein precursor knockout mice.","volume":"15","author":"Belaidi","year":"2018","journal-title":"Neurotherapeutics"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.celrep.2014.09.042","article-title":"A chaperome subnetwork safeguards proteostasis in aging and neurodegenerative disease.","volume":"9","author":"Brehme","year":"2014","journal-title":"Cell Rep."},{"key":"B8","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/s00018-022-04166-9","article-title":"Effects of oligomer toxicity, fibril toxicity and fibril spreading in synucleinopathies.","volume":"79","author":"Cascella","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s12640-016-9644-2","article-title":"Interference of \u03b1-synuclein uptake by monomeric \u03b2-amyloid1-40 and potential core acting site of the interference.","volume":"30","author":"Chan","year":"2016","journal-title":"Neurotoxic Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"111030","DOI":"10.1016\/j.ejrad.2023.111030","article-title":"Free water and iron content in the substantia nigra at different stages of Parkinson\u2019s disease.","volume":"167","author":"Chen","year":"2023","journal-title":"Eur. J. Radiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3389\/fnagi.2020.00112","article-title":"Plasma levels of \u03b1-synuclein, A\u03b2-40 and T-tau as biomarkers to predict cognitive impairment in Parkinson\u2019s disease.","volume":"12","author":"Chen","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"B12","volume-title":"Guidelines for the Diagnosis and Treatment of Parkinson\u2019s Disease (in Chinese).","year":"2016"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1523\/JNEUROSCI.5367-11.2012","article-title":"Endoplasmic reticulum stress is important for the manifestations of \u03b1-synucleinopathy in vivo.","volume":"32","author":"Colla","year":"2012","journal-title":"J. Neurosci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s00415-014-7560-z","article-title":"Correlates of cerebrospinal fluid levels of oligomeric- and total-\u03b1-synuclein in premotor, motor and dementia stages of Parkinson\u2019s disease.","volume":"262","author":"Compta","year":"2015","journal-title":"J. Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jns.2017.04.021","article-title":"Brain iron concentrations in regions of interest and relation with serum iron levels in Parkinson disease.","volume":"378","author":"Costa-Mallen","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.parkreldis.2015.06.009","article-title":"Haptoglobin phenotype modifies serum iron levels and the effect of smoking on Parkinson disease risk.","volume":"21","author":"Costa-Mallen","year":"2015","journal-title":"Park. Relat. Disord."},{"key":"B17","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-60327-254-4","volume-title":"The ELISA Guidebook","author":"Crowther","year":"2009"},{"key":"B18","doi-asserted-by":"publisher","first-page":"101414","DOI":"10.1016\/j.arr.2021.101414","article-title":"Lipocalin-2 as a link between ageing, risk-factor conditions and age-related brain diseases.","volume":"70","author":"Dekens","year":"2021","journal-title":"Ageing Res. Rev."},{"key":"B19","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00702-016-1642-2","article-title":"Relationship between the plasma levels of neurodegenerative proteins and motor subtypes of Parkinson\u2019s disease.","volume":"124","author":"Ding","year":"2017","journal-title":"J. Neural Transm."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: an iron-dependent form of nonapoptotic cell death.","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"key":"B21","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1212\/01.wnl.0000247740.47667.03","article-title":"Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030.","volume":"68","author":"Dorsey","year":"2007","journal-title":"Neurology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/mds.22919","article-title":"Plasma alpha-synuclein in patients with Parkinson\u2019s disease with and without treatment.","volume":"25","author":"Duran","year":"2010","journal-title":"Mov. Disord."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1093\/brain\/awz082","article-title":"Alpha-synuclein targets GluN2A NMDA receptor subunit causing striatal synaptic dysfunction and visuospatial memory alteration.","volume":"142","author":"Durante","year":"2019","journal-title":"Brain"},{"key":"B24","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s00401-017-1722-x","article-title":"Endocytic vesicle rupture is a conserved mechanism of cellular invasion by amyloid proteins.","volume":"134","author":"Flavin","year":"2017","journal-title":"Acta Neuropathol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"631210","DOI":"10.3389\/fneur.2021.631210","article-title":"Time-specific pattern of iron deposition in different regions in Parkinson\u2019s disease measured by quantitative susceptibility mapping.","volume":"12","author":"Fu","year":"2021","journal-title":"Front. Neurol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"645","DOI":"10.3109\/00207454.2014.961454","article-title":"Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson\u2019s disease diagnosis: a systematic review and meta-analysis.","volume":"125","author":"Gao","year":"2015","journal-title":"Int. J. Neurosci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorder Society\u2013sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov. Disord."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1002\/jmri.25431","article-title":"Influence of regional iron on the motor impairments of Parkinson\u2019s disease: a quantitative susceptibility mapping study.","volume":"45","author":"Guan","year":"2017","journal-title":"J. Magn. Reson. Imaging"},{"key":"B29","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1042\/BJ20150876","article-title":"Amyloid fibrils are the molecular trigger of inflammation in Parkinson\u2019s disease.","volume":"471","author":"Gustot","year":"2015","journal-title":"Biochem. J."},{"key":"B30","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/WNL.17.5.427","article-title":"Parkinsonism: onset, progression and mortality.","volume":"17","author":"Hoehn","year":"1967","journal-title":"Neurology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"27144","DOI":"10.1074\/jbc.M301988200","article-title":"Glycosylphosphatidylinositol-anchored ceruloplasmin is required for iron efflux from cells in the central nervous system.","volume":"278","author":"Jeong","year":"2003","journal-title":"J. Biol. Chem."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1001\/jamaneurol.2013.3861","article-title":"Association of cerebrospinal fluid \u03b2-amyloid 1\u201342, T-tau, P-tau181, and \u03b1-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.","volume":"70","author":"Kang","year":"2013","journal-title":"JAMA Neurol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1038\/ncomms2534","article-title":"Neuron-released oligomeric \u03b1-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia.","volume":"4","author":"Kim","year":"2013","journal-title":"Nat. Commun."},{"key":"B34","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S0962-8924(00)01852-3","article-title":"Aggresomes, inclusion bodies and protein aggregation.","volume":"10","author":"Kopito","year":"2000","journal-title":"Trends Cell Biol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1093\/brain\/awt192","article-title":"Disease duration and the integrity of the nigrostriatal system in Parkinson\u2019s disease.","volume":"136","author":"Kordower","year":"2013","journal-title":"Brain"},{"key":"B36","doi-asserted-by":"publisher","first-page":"679","DOI":"10.3233\/JAD-130458","article-title":"\u03b1-Synuclein in cerebrospinal fluid of Alzheimer\u2019s disease and mild cognitive impairment.","volume":"36","author":"Korff","year":"2013","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"119454","DOI":"10.1016\/j.neuroimage.2022.119454","article-title":"Evaluation of iron overload in nigrosome 1 via quantitative susceptibility mapping as a progression biomarker in prodromal stages of synucleinopathies","volume":"260","author":"Lancione","year":"2022","journal-title":"Neuroimage."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e0196056","DOI":"10.1371\/journal.pone.0196056","article-title":"ELISA method to detect \u03b1-synuclein oligomers in cell and animal models.","volume":"13","author":"Lassen","year":"2018","journal-title":"PLoS One"},{"key":"B39","doi-asserted-by":"publisher","first-page":"6016","DOI":"10.1523\/JNEUROSCI.0692-05.2005","article-title":"Intravesicular localization and exocytosis of alpha-synuclein and its aggregates.","volume":"25","author":"Lee","year":"2005","journal-title":"J. Neurosci."},{"key":"B40","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s00702-005-0427-9","article-title":"The plasma alpha-synuclein levels in patients with Parkinson\u2019s disease and multiple system atrophy.","volume":"113","author":"Lee","year":"2006","journal-title":"J. Neural Transm."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/mds.27479","article-title":"Susceptibility MRI captures nigral pathology in patients with Parkinsonian syndromes.","volume":"33","author":"Lewis","year":"2018","journal-title":"Mov. Disord."},{"key":"B42","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.expneurol.2006.12.003","article-title":"Plasma alpha-synuclein is decreased in subjects with Parkinson\u2019s disease.","volume":"204","author":"Li","year":"2007","journal-title":"Exp. Neurol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1136\/jnnp-2016-314857","article-title":"Plasma \u03b1-synuclein predicts cognitive decline in Parkinson\u2019s disease.","volume":"88","author":"Lin","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B44","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1159\/000511046","article-title":"Plasma total \u03b1-synuclein and neurofilament light chain: clinical validation for discriminating Parkinson\u2019s disease from normal control.","volume":"49","author":"Lin","year":"2020","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"B45","doi-asserted-by":"publisher","first-page":"12924","DOI":"10.1074\/jbc.M306390200","article-title":"Proteasomal inhibition by alpha-synuclein filaments and oligomers.","volume":"279","author":"Lindersson","year":"2004","journal-title":"J. Biol. Chem."},{"key":"B46","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrneurol.2014.232","article-title":"Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.","volume":"11","author":"Lle\u00f3","year":"2015","journal-title":"Nat. Rev. Neurol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1038\/s41467-018-04422-2","article-title":"\u03b1-Synuclein oligomers interact with ATP synthase and open the permeability transition pore in Parkinson\u2019s disease.","volume":"9","author":"Ludtmann","year":"2018","journal-title":"Nat. Commun."},{"key":"B48","doi-asserted-by":"publisher","first-page":"21490","DOI":"10.1074\/jbc.M113.545749","article-title":"Soluble, prefibrillar \u03b1-synuclein oligomers promote complex I\u2013dependent, Ca2 +\u2013induced mitochondrial dysfunction.","volume":"289","author":"Luth","year":"2014","journal-title":"J. Biol. Chem."},{"key":"B49","doi-asserted-by":"publisher","first-page":"101890","DOI":"10.1016\/j.pneurobio.2020.101890","article-title":"Ferroptosis and its potential role in the physiopathology of Parkinson\u2019s disease.","volume":"196","author":"Mahoney-S\u00e1nchez","year":"2021","journal-title":"Prog. Neurobiol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.pjnns.2015.08.004","article-title":"Plasma alpha-synuclein and tau protein as biomarkers of Parkinson\u2019s disease.","volume":"49","author":"Malec-Litwinowicz","year":"2015","journal-title":"Neurol. i Neurochirurgia Polska"},{"key":"B51","doi-asserted-by":"publisher","first-page":"7853","DOI":"10.1074\/jbc.RA118.001949","article-title":"Inflammation-induced iron transport and metabolism by brain microglia.","volume":"293","author":"McCarthy","year":"2018","journal-title":"J. Biol. Chem."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1046\/j.1460-9568.2002.02279.x","article-title":"Aggresome-related biogenesis of Lewy bodies.","volume":"16","author":"McNaught","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"B53","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1212\/WNL.39.3.349","article-title":"Neurobehavioral changes associated with caudate lesions.","volume":"39","author":"Mendez","year":"1989","journal-title":"Neurology"},{"key":"B54","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1212\/01.WNL.0000127517.33208.F4","article-title":"Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication.","volume":"62","author":"Miller","year":"2004","journal-title":"Neurology"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.3174\/ajnr.A4260","article-title":"Usefulness of quantitative susceptibility mapping for the diagnosis of Parkinson disease.","volume":"36","author":"Murakami","year":"2015","journal-title":"Am. J. Neuroradiol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2217\/bmm.15.89","article-title":"Value of cerebrospinal fluid \u03b1-synuclein species as biomarkers in Parkinson\u2019s diagnosis and prognosis.","volume":"10","author":"Parnetti","year":"2016","journal-title":"Biomark. Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"34690","DOI":"10.1074\/jbc.M111.261321","article-title":"Hsc70 protein interaction with soluble and fibrillar alpha-synuclein.","volume":"286","author":"Pemberton","year":"2011","journal-title":"J. Biol. Chem."},{"key":"B58","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease.","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson\u2019s disease.","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"key":"B60","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/ana.22311","article-title":"Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression.","volume":"69","author":"Shi","year":"2010","journal-title":"Ann. Neurol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00401-014-1314-y","article-title":"Plasma exosomal \u03b1-synuclein is likely CNS-derived and increased in Parkinson\u2019s disease.","volume":"128","author":"Shi","year":"2014","journal-title":"Acta Neuropathol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.3389\/fnagi.2024.01439","article-title":"Plasma \u03b1-synuclein levels in Parkinson\u2019s disease and their correlation with clinical features: a systematic review and meta-analysis.","volume":"16","author":"Shu","year":"2024","journal-title":"Front. Aging Neurosci."},{"key":"B63","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.parkreldis.2017.08.017","article-title":"Quantitative susceptibility mapping differentiates between Parkinsonian disorders.","volume":"44","author":"Sj\u00f6str\u00f6m","year":"2017","journal-title":"Parkinsonism Relat. Disord."},{"key":"B64","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.neulet.2014.09.049","article-title":"Increased plasma \u03b1-synuclein in patients with Parkinson\u2019s disease is correlated with disease severity.","volume":"583","author":"Sui","year":"2014","journal-title":"Neurosci. Lett."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1126\/science.1067122","article-title":"Toxic proteins in neurodegenerative disease.","volume":"296","author":"Taylor","year":"2003","journal-title":"Science"},{"key":"B66","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/mds.29592","article-title":"Brain iron deposition is linked with cognitive decline in Parkinson\u2019s disease.","volume":"39","author":"Thomas","year":"2024","journal-title":"Mov. Disord."},{"key":"B67","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.bbrc.2006.08.022","article-title":"Decreased \u03b1-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson\u2019s disease.","volume":"349","author":"Tokuda","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B68","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.parkreldis.2019.02.022","article-title":"Reduced caudate nucleus volumes and executive dysfunction in Parkinson\u2019s disease patients with mild cognitive impairment.","volume":"63","author":"Uchida","year":"2019","journal-title":"Parkinsonism Relat. Disord."},{"key":"B69","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3389\/fphar.2013.00103","article-title":"The interplay between iron accumulation, mitochondrial dysfunction, and inflammation during the execution step of neurodegenerative disorders.","volume":"4","author":"Urrutia","year":"2013","journal-title":"Front. Pharmacol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.tins.2010.09.004","article-title":"\u03b1-Synuclein and dopamine at the crossroads of Parkinson\u2019s disease.","volume":"33","author":"Venda","year":"2010","journal-title":"Trends Neurosci."},{"key":"B71","first-page":"913","article-title":"Iron deposition in different brain regions of Parkinson\u2019s disease patients and its correlation with clinical features: a quantitative susceptibility mapping study.","volume":"58","author":"Wang","year":"2016","journal-title":"Neuroradiology"},{"key":"B72","doi-asserted-by":"publisher","first-page":"134312","DOI":"10.1016\/j.neulet.2019.134312","article-title":"Serum \u03b1-synuclein in patients with multiple system atrophy and Parkinson\u2019s disease.","volume":"707","author":"Wang","year":"2019","journal-title":"Neurosci. Lett."},{"key":"B73","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/mrm.25358","article-title":"Quantitative susceptibility mapping (QSM): decoding MRI data for a tissue magnetic biomarker.","volume":"73","author":"Wang","year":"2015","journal-title":"Magn. Reson. Med."},{"key":"B74","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/jmri.25609","article-title":"Magnetic susceptibility quantification of brain iron in patients with Parkinson\u2019s disease by quantitative susceptibility mapping.","volume":"46","author":"Yao","year":"2017","journal-title":"J. Magn. Reson. Imaging"},{"key":"B75","first-page":"292","article-title":"Serum \u03b1-synuclein and its relation to cognitive function and motor severity in Parkinson\u2019s disease.","volume":"26","author":"Youssef","year":"2021","journal-title":"Neurosciences"},{"key":"B76","first-page":"1348823","article-title":"Iron accumulation in substantia nigra and putamen in Parkinson\u2019s disease evaluated by quantitative susceptibility mapping: a meta-analysis.","volume":"15","author":"Zeng","year":"2024","journal-title":"Front. Neurol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.3389\/fnins.2019.01306","article-title":"Quantitative susceptibility mapping of brain iron in patients with Parkinson\u2019s disease.","volume":"13","author":"Zhang","year":"2019","journal-title":"Front. Neurosci."},{"key":"B78","doi-asserted-by":"publisher","first-page":"869797","DOI":"10.3389\/fnagi.2022.869797","article-title":"Lewy body-associated proteins \u03b1-synuclein (\u03b1-syn) as a plasma-based biomarker for Parkinson\u2019s disease. Front","volume":"14","author":"Zhao","year":"2022","journal-title":"Aging. Neurosci."},{"key":"B79","first-page":"1452213","article-title":"Plasma \u03b1-synuclein as a predictor of cognitive impairment in Parkinson\u2019s disease: a longitudinal cohort study.","volume":"17","author":"Zhu","year":"2025","journal-title":"Front. Aging Neurosci."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.parkreldis.2022.01.007","article-title":"Plasma \u03b1-synuclein in Parkinson\u2019s disease: a meta-analysis on diagnostic performance and factors influencing its levels.","volume":"95","author":"Zubelzu","year":"2022","journal-title":"Parkinsonism Relat. Disord."},{"key":"B81","doi-asserted-by":"publisher","first-page":"44872","DOI":"10.1038\/srep44872","article-title":"Phenotype of postural instability\/gait difficulty in Parkinson disease: relevance to cognitive impairment and mechanism relating pathological proteins and neurotransmitters","volume":"7","author":"Zuo","year":"","journal-title":"Sci. Rep."},{"key":"B82","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.neulet.2017.04.042","article-title":"Plasma \u03b1-synuclein levels are correlated with cognitive and motor function in Parkinson\u2019s disease.","volume":"650","author":"Zuo","year":"","journal-title":"Neurosci. Lett."},{"key":"B83","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3389\/fnagi.2017.00433","article-title":"Plasma \u03b1-synuclein as a potential biomarker for Parkinson\u2019s disease: relationship with cognitive and motor performance.","volume":"9","author":"Zuo","year":"","journal-title":"Front. Aging Neurosci."}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2026.1740309\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T05:31:46Z","timestamp":1786685506000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2026.1740309\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":83,"alternative-id":["10.3389\/fnagi.2026.1740309"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2026.1740309","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"article-number":"1740309"}}